HEALTHCARE ROYALTY PARTNERS
Venture debtNew York · 27 people tracked
Investment thesis
HCRx focuses on advancing biopharmaceutical innovation through creative capital solutions, principally royalty monetization and corporate financing arrangements for life sciences and biopharma companies. Since inception the firm has committed more than $7 billion across over 110 biopharma products, supporting companies that develop and commercialize approved and near-approval therapeutics. Its financing model provides non-dilutive capital tied to product revenues and royalty streams rather than traditional early-stage venture equity.
Source: firm website, verified Aug 6, 2026.
Team · 27 people
from the firm's websiteWhat they invest in
from 12 of 79 portfolio companiesBiotech ×12Healthtech ×4Medical Devices ×4Deep Tech ×1
HQs:United States×11
Investments · 79 tracked
founders shown can be your intro pathBiotechHealthtechMedical DevicesLexington, US
Tom Dechaene(Director)Ozer Baysal(Executive Officer)Wadih Jordan(Director)Garo Armen(Executive Officer, Director)Robert Stein(Executive Officer)Timothy Wright(Director)
BiotechFremont, US
Annalisa Jenkins(Director)Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)Richard Rodgers(Director)Gordon Ringold(Director)Peter G. Schultz(Director)
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Barbara K Finck, M.D.(Executive Officer)Ali J. Satvat(Director)Mats Wahlstrom(Director)Alan C. Herman(Executive Officer)Dennis M. Lanfear(Executive Officer, Director)Jean-Frederic Viret, Ph.D.(Executive Officer)
BiotechNewton, US
Peter Honig(Director)Barry E. Greene(Director)Stuart Poulton(Executive Officer)Michael Mano(Executive Officer)Reshma Rangwala(Executive Officer)Richard Paulson(Executive Officer, Director)
BiotechSan Francisco, US
Lutz Lingnau(Director)Howard W. Robin(Executive Officer, Director)Gil M. Labrucherie(Executive Officer)Maninder Hora(Executive Officer)Stephen K. Doberstein(Executive Officer)John Nicholson(Executive Officer)
BiotechWashington, US
Kenneth T. Mills(Executive Officer, Director)John Daniel Kiser(Director)Allan M. Fox(Director)Benjamin Auspitz(Director)Donald J. Hayden, Jr.(Director)
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Reza Halse(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)
BiotechNewton Centre, US
Scott Minick(Director)John A. Scarlett(Director)Chaime Orlev(Executive Officer)Todd T. Foley(Director)Vincent Miles(Director)Ansbert K. Gadicke(Director)
Nanobiotix is a biotechnology company developing NBTXR3, a physics-based radioenhancer designed to increase radiotherapy effectiveness in solid tumors including head, neck, and lung cancers.
BiotechDeep TechMedical Devices
Fund performance · per public LP disclosures
as of Jun 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| HealthCare Royalty Partners III, L.P.LPs: Florida State Board of Administration | 2007 | — | 9.1% | 1.27x | 1.27x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What sectors does HEALTHCARE ROYALTY PARTNERS focus on?
- HEALTHCARE ROYALTY PARTNERS focuses on Biotech, Healthtech.
- Where is HEALTHCARE ROYALTY PARTNERS located?
- HEALTHCARE ROYALTY PARTNERS is headquartered in New York, US.
Images
Similar investors
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
B Capital is a venture and growth investment firm that backs technology companies, including a dedicated Resilience Tech practice focused on energy, industrial and infrastructure systems.